Vivos Therapeutics (NASDAQ: VVOS) Soars 8.82% on Clinical Milestone, Strategic Shifts in Pediatric Sleep Apnea Market

Vivos Therapeutics (NASDAQ: VVOS) surged 8.82% intraday, hitting a peak not seen since September 2025, as the stock climbed 4.14% over two days. This rally follows a robust clinical milestone and strategic shifts that position the company to capture growth in pediatric sleep apnea treatment.

The DNA Appliance, Vivos’ flagship device, demonstrated transformative potential in a multicenter trial, with 77% of participants achieving at least a 50% reduction in sleep apnea severity. The FDA’s 2024 clearance for treating severe pediatric cases has solidified its role as a non-surgical alternative to traditional adenotonsillectomy, a procedure with high relapse rates. These results, coupled with a 67.8% increase in airway volume observed in trials, underscore the device’s clinical credibility and market differentiation.

Expanding its product portfolio, Vivos has introduced pediatric appliances targeting early craniofacial development, which showed 61% of children reporting ADHD symptom resolution after seven months. The integration of laser treatments for tonsil swelling further enhances short-term patient outcomes, creating a layered therapeutic approach that strengthens its value proposition in a market where 90% of U.S. pediatric sleep apnea cases remain undiagnosed.

Strategic acquisitions, including The Sleep Center of Nevada, have reshaped Vivos’ business model. By transitioning from dentist-driven sales to direct patient engagement via sleep centers, the company now captures diagnostic and therapeutic revenue streams. This shift, while temporarily pressuring Q2 2025 revenue to $3.8 million, reflects a long-term play to scale through joint ventures and partnerships, such as its collaboration with MISleep Solutions in Michigan.

Despite financial challenges—including a 55% gross margin and rising operating expenses—Vivos’ stock remains volatile, driven by its regulatory edge as the only FDA-cleared non-surgical solution for pediatric sleep apnea. The global market for sleep apnea treatments, valued at $1.6 billion in the U.S. alone, offers substantial growth potential, particularly as the company advances clinical validation through global medical conferences and collaborations with leading researchers.

Investors are weighing near-term financial pressures against the company’s strategic pivot and clinical innovation. With a focus on expanding diagnostic capacity and treatment accessibility, Vivos is positioned to capitalize on unmet needs in a fragmented market, though operational execution and liquidity management will remain critical in the coming months.